XML 22 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Operating activities      
Net loss $ (324,277) $ (192,649) $ (176,273)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 3,577 2,901 2,438
Amortization of intangible assets 1,249 0 0
Stock-based compensation expense 26,240 18,073 18,039
Amortization of debt issuance costs 1,350 118 281
Loss on extinguishment of debt 2,209 0 0
Accretion of debt discount 15,889 0
Accretion of back-end fee on debt 50 658 171
Changes in operating assets and liabilities:      
Accounts receivable (5,515) 0 0
Inventory (7,032) 0 0
Prepaid expenses and other assets (5,514) (2,783) 191
Accounts payable 3,870 3,604 2,767
Accrued expenses and other 19,916 5,201 3,043
Accrued compensation 10,011 5,260 2,635
Net cash used in operating activities (257,977) (159,617) (146,708)
Investing activities      
Purchase of fixed assets (13,090) (3,001) (4,200)
PARI milestone upon FDA approval (1,724) 0 0
Net cash used in investing activities (14,814) (3,001) (4,200)
Financing activities      
Proceeds from issuance of 1.75% convertible senior notes due 2025 450,000 0 0
Payment on extinguishment of debt (2,835) 0 0
Payment of debt (55,000) 0 0
Proceeds from issuance of debt 0 0 30,000
Proceeds from issuance of common stock, net 0 377,656 0
Proceeds from exercise of stock options and ESPP 8,815 3,433 1,084
Payment of debt issuance costs (14,237) 0 (411)
Net cash provided by financing activities 386,743 381,089 30,673
Effect of exchange rates on cash and cash equivalents (45) 103 (50)
Net increase (decrease) in cash and cash equivalents 113,907 218,574 (120,285)
Cash and cash equivalents at beginning of period 381,165 162,591 282,876
Cash and cash equivalents at end of period 495,072 381,165 162,591
Supplemental disclosures of cash flow information:      
Cash paid for interest 6,289 5,165 3,608
Cash paid for taxes, net $ 154 $ 166 $ 85
1.75% Convertible Senior Note Due 2025 | Convertible Notes Payable      
Supplemental disclosures of cash flow information:      
Proceeds from issuance of 1.75% convertible senior notes due 2025 1.75%